BIBLIOGRAPHY
Belton, O., and Fitzgerald, D. Cyclooxygenase-2 inhibitors and atherosclerosis. J. Am. Coll. Cardiol., 41:1820–2, 2003.
Bing, R. J., and Lomnicka, M. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? J. Am. Coll. Cardiol., 39:521–522, 2002.
Bresalier, MD, R. S., Sandler, MD, R. S., Quan, PhD, H. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med., 352:1092–1102, Number 11, March 17, 2005.
Burleigh, M. E., Babaev, V. R., Oates, J. A. et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation, 105:18 16–23, 2002.
Burnett, M. S., Gaydos, C. A., Madico, G. E. et al. Atherosclerosis in ApoE knockout mice infected with multiple pathogens. J. Infect. Dis., 183;226–31, 2001.
Drazen, MD., J. M. et al. COX-2 inhibitors — A lesson in unexpected problems. N. Engl. J. Med., 352:1131–1132, Number 11, March 17, 2005.
Furberg, C. D., Psaty, B. M., FitzGerald, G. A. et al. Parecoxib, valdecoxib, and cardiovascular risk. Circulation, 111:249, 2005.
Hsich, E., Zhou, Y. F., Paigen, B. et al. Cytomegalovirus infection increases development of atherosclerosis in apolipoprotein-E knockout mice. Atherosclerosis, 156:23–8, 2001.